S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
"Prepare for Five Years of Famine" (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
"Prepare for Five Years of Famine" (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
MUST WATCH: Unusual 3-second financial maneuver (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
"Prepare for Five Years of Famine" (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
"Prepare for Five Years of Famine" (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
MUST WATCH: Unusual 3-second financial maneuver (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
"Prepare for Five Years of Famine" (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
"Prepare for Five Years of Famine" (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
MUST WATCH: Unusual 3-second financial maneuver (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
"Prepare for Five Years of Famine" (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
"Prepare for Five Years of Famine" (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
MUST WATCH: Unusual 3-second financial maneuver (Ad)
OTCMKTS:QBIO

Q BioMed - QBIO Stock Forecast, Price & News

$0.04
+0.01 (+29.41%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.04
$0.04
50-Day Range
$0.04
$0.18
52-Week Range
$0.04
$0.90
Volume
2.26 million shs
Average Volume
302,904 shs
Market Capitalization
$1.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
QBIO stock logo

About Q BioMed (OTCMKTS:QBIO) Stock

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutics to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

Receive QBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Q BioMed and its competitors with MarketBeat's FREE daily newsletter.

QBIO Stock News Headlines

Q BioMed Inc. Provides Update to Shareholders
Q BioMed Inc (QBIO)
Q BioMed outlines strategic direction and goals for 2022
Q BioMed Outlines Strategic Direction for 2022
Q BioMed Inc. Provides Shareholder Update
See More Headlines
Receive QBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Q BioMed and its competitors with MarketBeat's FREE daily newsletter.

QBIO Company Calendar

Last Earnings
7/14/2021
Today
8/09/2022
Fiscal Year End
11/30/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:QBIO
Previous Symbol
NASDAQ:QBIO
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Net Income
$-8,240,000.00
Net Margins
-1,868.26%
Pretax Margin
-1,868.51%

Debt

Sales & Book Value

Annual Sales
$200,000.00
Book Value
($0.37) per share

Miscellaneous

Free Float
N/A
Market Cap
$1.99 million
Optionable
Not Optionable
Beta
2.19

Key Executives

  • Mr. Denis D. Corin (Age 49)
    Chairman, CEO & Pres
    Comp: $300k
  • Mr. William S. Rosenstadt (Age 54)
    Chief Legal Officer, Gen. Counsel & Director
    Comp: $300k
  • Mr. David Laskow-Pooley (Age 68)
    VP of Product Devel.
  • Mr. Robert Derham
    VP of Orphan Products
  • Mr. Ari Jatwes
    Bus. Devel. Analyst
  • Dr. Amy Ripka
    Medicinal Chemistry Advisor













QBIO Stock - Frequently Asked Questions

How has Q BioMed's stock performed in 2022?

Q BioMed's stock was trading at $0.43 on January 1st, 2022. Since then, QBIO stock has decreased by 89.8% and is now trading at $0.0440.
View the best growth stocks for 2022 here
.

Are investors shorting Q BioMed?

Q BioMed saw a decline in short interest in July. As of July 15th, there was short interest totaling 100 shares, a decline of 99.5% from the June 30th total of 19,200 shares. Based on an average daily trading volume, of 844,800 shares, the short-interest ratio is presently 0.0 days.
View Q BioMed's Short Interest
.

How were Q BioMed's earnings last quarter?

Q BioMed Inc. (OTCMKTS:QBIO) released its earnings results on Wednesday, July, 14th. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.04. The company had revenue of $0.05 million for the quarter.

What other stocks do shareholders of Q BioMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Q BioMed investors own include NVIDIA (NVDA), Micron Technology (MU), Washington Trust Bancorp (WASH), Nokia Oyj (NOK), Cisco Systems (CSCO), Inovio Pharmaceuticals (INO), Intel (INTC), OPKO Health (OPK) and AT&T (T).

What is Q BioMed's stock symbol?

Q BioMed trades on the OTCMKTS under the ticker symbol "QBIO."

How do I buy shares of Q BioMed?

Shares of QBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Q BioMed's stock price today?

One share of QBIO stock can currently be purchased for approximately $0.04.

How much money does Q BioMed make?

Q BioMed (OTCMKTS:QBIO) has a market capitalization of $1.99 million and generates $200,000.00 in revenue each year. The company earns $-8,240,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis.

How many employees does Q BioMed have?

Q BioMed employs 3 workers across the globe.

How can I contact Q BioMed?

Q BioMed's mailing address is 366 MADISON AVENUE 3RD FLOOR, NEW YORK NY, 10017. The official website for the company is www.qbiomed.com. The company can be reached via phone at (646) 889-2226.

This page (OTCMKTS:QBIO) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.